Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target

<p>Table S9 shows the (a) differentially expressed transcripts and (b) altered pathways as identified by GSEA from the ELAVL1 knockdown human primary AML RNA-sequencing data set.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Ana Vujovic (15207479) (author)
مؤلفون آخرون:	Laura de Rooij (15207482) (author), Ava Keyvani Chahi (15207485) (author), He Tian Chen (15207488) (author), Brian A. Yee (15207491) (author), Sampath K. Loganathan (15121740) (author), Lina Liu (15207494) (author), Derek C.H. Chan (15207497) (author), Amanda Tajik (15207500) (author), Emily Tsao (15207503) (author), Steven Moreira (14937143) (author), Pratik Joshi (15207506) (author), Joshua Xu (15207509) (author), Nicholas Wong (15207512) (author), Zaldy Balde (15207515) (author), Soheil Jahangiri (15207518) (author), Sasan Zandi (15207521) (author), Stefan Aigner (15207524) (author), John E. Dick (14937554) (author), Mark D. Minden (14961936) (author), Daniel Schramek (15121764) (author), Gene W. Yeo (15207527) (author), Kristin J. Hope (15207530) (author)
منشور في:	2025
الموضوعات:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Drug Targets Oncoprotein & tumor suppressor drug targets Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Oncogenes & Tumor Suppressors Oncogenes Preclinical Models Xenograft models Small Molecule Agents Stem Cell Biology Cancer stem cells Hematopoiesis
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
حسب: Ana Vujovic (15207479)
منشور في: (2025)

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
حسب: Amir T. Fathi (15313195)
منشور في: (2025)

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
حسب: Amir T. Fathi (15313195)
منشور في: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
حسب: Smruthy Sivakumar (15053536)
منشور في: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
حسب: Long Jiang (14956159)
منشور في: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
حسب: Long Jiang (14956159)
منشور في: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
حسب: Long Jiang (14956159)
منشور في: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
حسب: Anne-Florence Blandin (15056366)
منشور في: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
حسب: Yun-Guang Hong (14960966)
منشور في: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
حسب: Yun-Guang Hong (14960966)
منشور في: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
حسب: Yun-Guang Hong (14960966)
منشور في: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
حسب: Yun-Guang Hong (14960966)
منشور في: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
حسب: Yun-Guang Hong (14960966)
منشور في: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
حسب: Yun-Guang Hong (14960966)
منشور في: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
حسب: Yuanqing Ma (15052437)
منشور في: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
حسب: Feng Wang (44414)
منشور في: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
حسب: Feng Wang (44414)
منشور في: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
حسب: Feng Wang (44414)
منشور في: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
حسب: Feng Wang (44414)
منشور في: (2025)

Supplementary Tables S3-5 from Activation of the cGAS/STING Axis in Genome-Damaged Hematopoietic Cells Does Not Impact Blood Cell Formation or Leukemogenesis
حسب: Nicole Dressel (16918215)
منشور في: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ol4pr658smpjg5mu9l628r4paa